Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
sintilimab + apatinib + nab-paclitaxel + carboplatin
- Development stage
- Unknown
- Lead developer
- Innovent Biologics
- Modality
- Nucleic Acid-Directed Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Covalent Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Administration
- Intravenous, Oral
01
Overview
A combination therapy consisting of sintilimab (anti-PD-1 antibody), apatinib (anti-angiogenic agent), nab-paclitaxel (chemotherapy), and carboplatin (chemotherapy). This regimen has shown promising efficacy in the neoadjuvant treatment of early triple-negative breast cancer with a pathological complete response rate of 70.6% in the NeoSAC trial. The combination works by enhancing immune response in the tumor microenvironment while directly targeting cancer cells.
- Brand names
- TyvytAiTanAbraxane
- Other names
- Sintilimab + Apatinib + Albumin-Bound Paclitaxel + Carboplatin
02
Targets
TUBB (Tubulin (alpha and beta subunits))DNAVEGFR2 (Vascular endothelial growth factor receptor 2)PDCD1 (Programmed cell death protein 1 receptor)
Beyond the preview
Go deeper on sintilimab + apatinib + nab-paclitaxel + carboplatin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on sintilimab + apatinib + nab-paclitaxel + carboplatin.